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Abstract Fostriecin, an antitumor antibiotic produced by 
Streptomyces pulveraceus, is a strong inhibitor of type 2A 
(PP2A; IC50 3.2 nM) and a weak inhibitor of type 1 (PPl ; IC50 
131 uM) serine/threonine protein phosphatases. Fostriecin has no 
apparent effect on the activity of PP2B, and dose-inhibition 
studies conducted with whole cell homogenates indicate that 
fostriecin also inhibits the native forms of PPl and PP2A. 
Studies with recombinant PP1/PP2A chimeras indicate that 
okadaic acid and fostriecin have different binding sites. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Fostriecin (Fig. 1) is an antitumor antibiotic isolated from 
the fermentation beer of Streptomyces pulveraceus (subspecies 
fostreus) [1,2] that is under development as an anticancer 
agent [3]. Fostriecin exhibits antitumor activity against a 
wide spectrum of tumor cells in vitro and has excellent activity 
against L1210 and P388 leukemias in vivo [4,5]. Currently, 
fostriecin is under evaluation as an antitumor drug in clinical 
trials. 
The cellular mechanisms underlying the antitumor activity 
of fostriecin have been under investigation for several years. 
Early studies indicated that fostriecin rapidly inhibits DNA, 
RNA and protein synthesis [6]. Although these studies dem-
onstrated that fostriecin affects a process essential for replica-
tion and transcription, no direct effect on DNA polymerase, 
RNA polymerase or enzymes within the purine or pyrimidine 
biosynthetic pathways was noted [3,6]. Subsequently, fostrie-
cin was shown to block cells in the G2 phase of the cell cycle 
and to have inhibitory effects on partially purified type II 
topoisomerase from Ehrlich ascites carcinoma [7]. However, 
fostriecin is distinctly different from previously described in-
hibitors of topoisomerase II in that it does not cause protein-
associated DNA strand breaks [7]. 
Recent studies suggest that the antitumor activity of fostrie-
cin may originate from its ability to interfere with the revers-
ible phosphorylation of proteins that are critical for progres-
sion through the cell cycle [8-10]. Fostriecin has been reported 
to inhibit a mitotic entry checkpoint [8], and it induces chro-
mosome condensation in interphase cells in a manner compa-
*Corresponding author. Fax: (1) (334) 460-6127. 
E-mail : honkanen@sungcg.usouthal.edu 
rable to okadaic acid, a known inhibitor of protein phospha-
tases types 1 (PPl) and 2A (PP2A) [9]. Fostriecin induced 
chromosome condensation correlates with an increase in his-
tone H2A and H3 phosphorylation in mouse mammary tumor 
cells, and fostriecin induces the hyperphosphorylation of vi-
mentin, which correlates with the reorganization of intermedi-
ate filaments in hamster kidney cells [10]. Furthermore, fos-
triecin inhibits the dephosphorylation of a phosphopeptide 
(KRphospho-T-IRR; Upstate Biotechnology, Inc.) by parti-
ally purified PPl and PP2A [8]. 
Other inhibitors of PPl and PP2A, notably okadaic acid 
[11,12] and microcystin-LR [13,14], have been reported to 
have tumor promoting activity [15,16], while cantharidin 
[17,18] and structural derivatives of cantharidin, have antitu-
mor activity against KB cells in culture and on reticulocell 
sarcoma and ascites hepatoma in mice [19,20]. Therefore, if 
the antitumor activity of fostriecin results from the inhibition 
of PPase activity, the further characterization of the inhibitory 
effects of fostriecin on specific PPase is clearly warranted. The 
present study characterizes the inhibitory activity of fostriecin 
employing the purified catalytic subunits of serine/threonine 
protein phosphatases types 1 (PPl), 2A (PP2A) and 2B 
(PP2B). This study also characterizes the effects of fostriecin 
on native PPases contained whole cell homogenates of the 
well characterized Rin5mF insulinoma cells [21,22]. These 
studies indicate that fostriecin is a > 10000-fold more potent 
inhibitor of PP2A than PPl and has no apparent effect on 
PP2B. Furthermore, the inhibition of PPase activity with both 
the purified PPase and the dilute cell homogenate correlates 
well with the concentrations that have antitumor activity in 
vitro and in vivo [1-4], adding additional support to the con-
cept that the antitumor activity of fostriecin is associated with 
the inhibition of PPase activity. 
2. Materials and methods 
2.1. Materials 
Phosphorylase kinase (EC 2.7.1.38) from rabbit muscle, PP2B (cal-
cineurin) and calmodulin (phosphodiesterase 3',5'-cyclic nucleotide 
activator) from bovine brain, and /7-nitrophenyl phosphate (PNPP) 
were obtained from Sigma Company and utilized without further 
purification. Fostriecin (NSC 339638, lot 700-95-202) was generously 
donated by the Division of Cancer Treatment, National Cancer In-
stitute and Parke-Davis. Okadaic acid was generously provided by Dr. 
R. Dickey. 
2.2. Preparations of phosphoprotein substrates 
[32P]Phosphorylase a from rabbit muscle was prepared essentially 
according to the methods of Brautigan and Shriner [23] and described 
previously [13,24,27]. Briefly, 20 mg of phosphorylase b was incubated 
with 1.4 mCi of [γ-32Ρ]ΑΤΡ (Ιχΐθ 4 cpm/pmol) and 100 units of 
phosphorylase kinase for 1.5 h at pH 8.2 and 30°C. After the phos-
phorylation reaction was terminated, phosphorylase a was crystallized 
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by adjustment of the pH to 6.8 and placing the mixture on ice. The 
crystals were collected by centrifugation and washed extensively with 
ice cold 20 mM Tris-HCl, 50 mM 2-mercaptoethanol, pH 6.8 (buffer 
A). After washing, the crystals were dissolved by the addition of 100 
mM NaCl and heating to 30°C. This solution was then passed 
through a Sephadex G-25 column and the protein containing fraction 
was dialyzed against buffer A [24]. This procedure produces phos-
phorylase a with a specific activity of ~5.8X 106 cpm/nmol of incor-
porated phosphate. 
2.3. Determination of protein phosphatase activity 
The catalytic subunit of PPl was purified to apparent homogeneity, 
demonstrating a single band upon sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and silver staining, essentially 
according to the methods of Brautigan et al. [26] and described in 
Honkanen et al. [17,27,28]. The catalytic subunit of PP2A was puri-
fied to apparent homogeneity as described by Pallas et al. [29], using 
G-75 Sephadex in the place of Ultrogel-AcA44 as previously reported 
[24-28]. 
Protein phosphatase activity against phosphorylase a was deter-
mined by the liberation of 32P using either the purified catalytic sub-
units of the indicated protein phosphatases (Fig. 2) or a dilute whole 
cell homogenate of RIN5mF insulinoma cells (Fig. 3). Assays (80 μΐ 
total volume) containing 50 mM Tris-HCl, pH 7.4, 0.5 mM DTT, 
1 mM EDTA and [32P]phosphorylase a (1-2 μΜ Ρ04) were conducted 
as described by Honkanen et al. [17,24]. For all reactions the dephos-
phorylation of substrate was < 10% of the total, and reactions were 
linear with respect to enzyme concentration and time. [32P]Phosphate 
liberated by the enzymes was extracted as a phosphomolybdate com-
plex and measured according to the methods of Killilea et al. [30]. 
Inhibition of phosphatase activity was determined by the addition of 
fostriecin or okadaic acid to the assay mixture 10 min before initiation 
of the reaction with the addition of substrate [24]. Fostriecin was 
dissolved in phosphate buffered saline containing 0.1 mM ascorbic 
acid (as an antioxidant), which was added in equal amounts to con-
trols. Unless indicated otherwise, inhibition assays, conducted with 
purified rabbit muscle PPl or PP2A, contained 200 pM PPl or 225 
рМ РР2А, having phosphatase activity against phosphorylase a of 
4.2 ±0.25 and 1.1 ±0.22 μpiιοΐ min - 1 mg of protein -1, respectively. 
The phosphorylase a phosphatase activity of recombinant human 
PP la and the PP1/PP2A chimera (CRHM2) was 1.1 ±0.1 and 
0.95 ± 0.09 μpiιοΐ min - 1 mg of protein -1, respectively. For comparison 
studies conducted with CRHM2, PP2A and recombinant PPl (Fig. 5), 
the amount of each PPase was adjusted so that equal amounts ( ~ 500 
pM) of each PPase were contained in the assay. For kinetic analysis, 
1-30 μΜ phosphorylase a (final concentration) was used as substrate. 
Кш and Vmex values were estimated from Lineweaver-Burke plots. 
PP2B activity was measured using (PNPP) in the presence of Ca2+ 
and calmodulin as described previously [17,24]. Briefly, the assay (180 
μΐ total volume) containing 50 mM Tris base, pH 8.5, 20 mM MgCl2, 
0.25 mM DTT, 0.2 μΜ calmodulin, 0.1 mM CaCl2, and 20 mM 
PNPP, was conducted at 30°C for 15 min. The reaction was termi-
nated by the addition of 900 μΐ of 1 M NaC03 , pH 10, and change in 
absorbance, measured at 410 nm, was used to calculate phosphatase 
activity. 
2.4. Construction of PP1IPP2A chimeras 
A clone containing the full-length PP2A cDNA from bovine brain 
was generously provided by Shu-Chih Chen (Pacific Northwest Re-
search Foundation). PCR was used to amplify the entire coding re-
gion of PP2A, and the PCR product was subcloned into pBluescript 
(Stratagene). Recombinant human PP la was obtained by PCR am-
plification of human retina cDNA using PP la specific primers 
(RH18; 5'-CTGGACGAATTCATGTCCGACAGCGAG-3' and 
RH17; 5'-TTATTCAAGCTTCCAGATGGGTTGCC-3'). The PCR 
product produced was subcloned into pBluescript and sequenced. The 
З'-coding region (bp 796-933) of PP2A was then substituted for the 
З'-coding region of PPl (816-1021) using the gene fusion techniques 
described by S. Barik [31]. Briefly, a 30 base oligonucleotide contain-
ing 15 bases complementary to PPl (bp 803-816) and 15 bases of 
PP2A (bp 796-811) was synthesized. This PP1/PP2A primer was 
used in combination with a PP2A specific antisense primer (SB8; 
5'-GGGCCGGATCCATCAC AGGAAGTAGTC-3') to amplify the 
C-terminal region of PP2A (bp 796-933). The PCR product produced 
was then employed as a 'mega-primer' in combination with a PPl 
specific primer (RH18) to amplify PP la cDNA. After 8 cycles, an 
aliquot of the PCR reaction was diluted and used as template for 
30 additional rounds of amplification using an N-terminal PPl specific 
sense (RH18) primer in combination with a PP2A C-terminal specific 
antisense (SB8) primer. The PCR product produced was then sub-
cloned into pBluescript and sequenced to ensure the fidelity of the 
PPl/PP2A-chimera (CRHM2). 
2.5. Expression of recombinant PPases 
The coding region of PP la and the chimera, CRHM2, were sub-
cloned behind the tac promoter in pKK223-2 (Pharmacia) and used to 
transform a competent strain of E. coli (TOP 10 or JM105). For 
expression, the bacteria were grown in LB-amp supplemented with 
1 mM MnCl2 and 50 μΜ IPTG at 18°C for ~ 7 2 h. The bacteria 
were then collected by centrifugation and lysed with a French press. 
The recombinant PPases were purified employing essentially the same 
procedures used to purify the native catalytic subunits of PPl and 
PP2A from animal tissue, omitting the methanol precipitation step 
prior to chromatography on heparin-Sepharose; like PPl, CRHM2 
is retained on Heparin-Sepharose and elutes upon the addition of 
buffer containing 1 M NaCl (Walsh and Honkanen, unpublished ob-
servation). 
3. Results 
The dephosphorylation of phosphorylase a by the purified 
catalytic subunit of P P l or PP2A is inhibited by fostriecin, 
which has no apparent effect on the activity of PP2B at the 
concentrations tested (Fig. 2). When diluted below the titra-
tion endpoint, defined as the concentration of enzyme after 
which further dilution no longer affects the IC 5 0 [13,24], fos-
triecin inhibits the activity of both PP l and PP2A in a dose-
dependent manner, inhibiting PP2A (ICso = 3 .2±0 .2 n M ; 
mean ± S.D., n-4) at a ~ 40 000 fold lower concentration 
than P P l (IC5 0 = 131 ± 13.1 μ Μ ; m e a n ± S . D . , n = 4). 
To determine whether fostriecin inhibits the activity of the 
native forms of P P l and PP2A at a comparable concentration 
to that observed with the respective purified catalytic subunits, 
we examined the effects of fostriecin in dilute (65 μg protein/ 
ml) whole cell homogenates of R I N m 5 F insulinoma cells (Fig. 
3). Fostriecin inhibits the divalent cation-independent protein 
phosphatase activity in the whole-cell homogenate in a dose-
dependent manner, with complete inhibition requiring the ad-
dition of ~ 10 m M fostriecin. Nonlinear regression analyses 
of the dose-inhibition curve obtained with fostriecin indicates 
that the divalent cation-independent phosphatase activity con-
tained in the R I N m 5 F cell homogenate best fits a multi-site 
model, which is consistent with that predicted for an assay 
containing a mixture of at least P P l and PP2A [13,17,24]. 
To further characterize the interaction of fostriecin with 
PP l and PP2A, a series of PP1/PP2A chimeras was con-
structed. The goal was to identify the fostriecin binding do-
main by producing mutat ions in PP1/PP2A displaying altered 
sensitivity to fostriecin. Unfortunately, most of the constructs 
had markedly decreased activity against phosphorylase a or 
altered kinetic properties (i.e. increased Km and decreased 
F m B ) . This suggests that the mutat ions produce conforma-
Fostriecin 
Fig. 1. Structure of fostriecin. 
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Fig. 2. Inhibition of protein phosphatases by fostriecin. The purified 
catalytic subunits of PP1 (0) and PP2A ( Δ , ν ) were assayed, using 
[32P]labeled phosphorylase a as a substrate, and PP2B (·) using 
PNPP as described in Section 2. The data are expressed as % of 
controls, with control activity against phosphorylase a being 
4.2±0.25 and 1.1 ±0.22 umol min"1 mg of protein"1 for PP1 and 
PP2A, respectively. Fostriecin was mixed with the enzymes for 10 
min at 23°C prior to the initiation of the reaction with the addition 
of substrate. Inhibition assays contained ~200 pM PP1, 200 pM 
PP2A ( Δ ) or 100 pM PP2A (v). The data represent the 
mean ± S.D. (n - 8) of data obtained from at least three separate ex-
periments employing two different preparations of each enzyme 
tested. 
tional changes in the enzyme, which makes it difficult to assess 
if an observed change in sensitivity to fostriecin results from a 
mutation occurring directly in the inhibitor binding domain or 
to the masking-unmasking of the binding domain subsequent 
to a conformational change in the enzyme. Nonetheless, one 
construct, CHRM2, was found to have kinetic properties (Km 
10.2 μΜ, Fmax 48 μpiιοΐ mg
- 1 min- 1) comparable to that of 
recombinant human PPloc (Km 10.4, Vmex 49.3 μιηοΐ mg
- 1 
min"1). In CRHM2, the COOH-terminal domain of PP1 
(816-1021) is replaced by the COOH-terminal region of 
PP2A (bp 796-933), with the fusion occurring at a domain 
(SAPNYC) conserved in both PP1 and PP2A. As seen in Fig. 
4, both endogenous PP2A and CRHM2 are potently inhibited 
by okadaic acid. However, when the concentration of either 
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Fig. 3. Effect of fostriecin on protein phosphatase activity contained 
in a homogenate of RINm5F insulinoma cells. Cells from a single 
~50% confluent 100 mm dish were rinsed with 4°C phosphate buff-
ered saline, scraped and sonicated in 1 ml of Tris buffer (20 mM 
Tris-HCl, 1 mM EDTA, and 2 mM dithiothreitol, pH 7.4). The ho-
mogenate was then diluted below the titration endpoint (the concen-
tration after which further dilution no longer affects the IC50 
[13,24], ~65 μg protein/ml) and assayed for phosphorylase a phos-
phatase activity as described in Fig. 2. Each point represents the 
mean ± S.D. of three experiments conducted in triplicate. 
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Fig. 4. Effect of enzyme concentration on the inhibition of purified 
catalytic subunits of PP2A and a recombinant PP1/PP2A chimera 
(CRHM2). Phosphatase activity was determined with phosphorylase 
a as a substrate (see Section 2 for details), and assays were con-
ducted as described in Fig. 2, with the concentration of PP2A added 
to the assay adjusted to 5 nM (o), 500 pM (D), 200 pM ( Δ ) and 
100 pM (v) and the concertina of CRHM2 adjusted to 5 nM (·) 
500 pM (■) and 200 pM (A) . Okadaic acid was mixed with each 
enzyme 10 min at 23°C prior to the addition of substrate. Each 
point represents the mean ± S.D. (n = 3). 
PPase exceeds that of okadaic acid, the apparent IC50 of oka-
daic decrease with dilution (Fig. 4A,B). This 'shift in IC50' 
appears to result from the titration of okadaic acid from the 
assay by the catalytic subunit of PP2A or CHRM2, because it 
is not observed in assays containing very low concentrations 
of enzymes and is also observed with microcystin-LR [13] and 
nodularin [24]. 
Once diluted below the titration endpoint, okadaic acid in-
hibits the activity of native PP2A and CRHM2 in a dose-
dependent manner, inhibiting the activity of PP2A at a 
slightly lower concentration than CRHM2. This difference 
could indicate that part of the high affinity okadaic acid bind-
ing domain contained in PP2A has been replaced by a region 
of PP1 that renders CRHM2 less sensitive to okadaic acid. 
However, when compared to endogenous PP2A, CRHM2 is 
less active against phosphorylase a. Thus, the difference in 
sensitivity to okadaic acid could also result from a titration 
artifact produced by the presence of aberrantly folded re-
combinant CRHM2 that is inactive yet still capable of binding 
okadaic acid. Nonetheless, when the inhibitory effect of fos-
triecin is compared in assays containing equal amounts of 
endogenous PP2A and CRHM2 (effectively neutralizing any 
potential titration effects) CRHM2 is inhibited by okadaic 
acid at concentrations comparable to that of PP2A (Fig. 5). 
This is consistent with studies indicating that the okadaic acid 
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Fig. 5. Comparison of the inhibitory effect of okadaic acid and fos-
triecin on the activity of the catalytic subunit of PP2A (D), recombi-
nant PPla (0) and a recombinant CRHM2 (■). Assays were con-
ducted as described in Fig. 2 with all three enzymes added in 
comparable amounts (~500 pM). 
binding site is contained in the C-terminal region of PP2A or 
a combination of the C-terminal region of PP2A and other 
regions conserved in both PP1 and PP2A [32-35]. In contrast, 
CRHM2 is inhibited by fostriecin at concentrations similar to 
those which inhibit PPla , suggesting that the high affinity 
fostriecin binding domain is located in a different region of 
PP2A. 
4. Discussion 
To date, several potent inhibitors of PP1 and PP2A have 
been identified, including: okadaic acid, a polyether carbox-
ylic acid produced by several species of marine dinoflagellates 
[11,12]; > 50 variants of microcystin, a family of cyclic hep-
tapeptides produced by certain strains of cyanobacteria 
[13,36,37]; nodularin, a cyclic pentapeptide produced by 
Nodularia spumigena [24]; motuporin, a structural variant of 
nodularin [34]; calyculin A, a spiro ketal obtained from a 
marine sponge [39]; tautomycin, a dialkylmaleic anhydride 
produced by a strain of Streptomyces spiroverticillatus [40-
42]; and cantharidin, an oxabicycloheptane-2,3-dicarboxylic 
acid anhydride that is a natural toxicant of blister beetles 
[17,18]. This study confirms that fostriecin has inhibitory ac-
tivity against PP2A and PP1, and shows that fostriecin has no 
apparent effect on the Ca2+/calmodulin-dependent phospha-
tase, PP2B. In addition, fostriecin inhibits the divalent cation-
independent PPase activity contained in dilute cell homoge-
nates of RINm5F insulinoma cells at concentrations compar-
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able to that which affect the purified catalytic subunits (Fig. 
3). Thus, fostriecin represents yet another example of a natu-
ral compound with inhibitory activity against both the native 
and purified catalytic subunits of PP1 and PP2A. Further-
more, fostriecin is relatively water soluble and utilizes the 
reduced folate carrier system to enter cells [43,45]. This allows 
for the efficient delivery and uptake of fostriecin by many 
types of cultured cells (Walsh and Honkanen, unpublished 
observation), suggesting that fostriecin will also prove useful 
as a research tool. 
Due to its ability to inhibit PP2A at 10-100-fold lower 
concentrations than PP1, okadaic acid has proven valuable 
as a research tool for determining the physiological and 
pathological roles of these serine/threonine protein phospha-
tases [12,44]. Like okadaic acid, fostriecin is a more potent 
inhibitor of PP2A than PP1, and the purified catalytic subunit 
of PP2A from muscle is inhibited by fostriecin at a concen-
tration that is ~ 40 000 times lower than that required to 
inhibit the activity of purified PP1 (Fig. 2). Under identical 
assay conditions okadaic acid is more potent inhibitor of both 
PP2A and PP1 (Fig. 4C) [11,12,24,28]. However, the greater 
selectivity of fostriecin for PP2A should prove beneficial for 
distinguishing the activity of PP1 and PP2A in dilute cell 
homogenates, and the reduced potency of fostriecin may 
also diminish the potential for titration artifacts that often 
complicate the use of okadaic acid in studies designed to dis-
tinguish the activity of PP2A from that of PP1. In addition, 
the increased selectivity of fostriecin for PP2A may be useful 
in studies designed to clarify the paradox where inhibitors of 
the same PPases can act as antitumor antibiotics or tumor 
promoting agents [3,11-20]. Still fostriecin is sensitive to oxi-
dation [38], rendering it less stable than okadaic acid (Walsh 
and Honkanen, unpublished observation). 
The recent elucidation of the x-ray crystal structure of the 
catalytic subunit of PP1 complexed with microcystin-LR in-
dicates that the COOH-terminal subdomain sits on the NH2-
terminal subdomain, forming three surface grooves (a hydro-
phobic groove, an acidic groove and a COOH-terminal 
groove), with the active site situated at the bifurcation point 
of the three grooves [35,46]. Microcystin-LR covalently binds 
to Cys-273 in PP1, which is adjacent to the predicted active 
site, and several studies predict that microcystin inhibits PP1 
activity by blocking access to or interacting with key residues 
in the active site [34,35,46]. Modeling studies based on the 
crystal structures of free okadaic acid suggest that okadaic 
acid binds to the same region as microcystin [34], and muta-
genesis analyses of PP1 suggest an important role of the ßl2/ 
ßl3 loop (residues 272-276) in the inhibition of PP1 and 
PP2A by microcystin-LR, okadaic acid and calyculin A [32-
35,46]. The inhibition studies conducted with CRHM2, where 
the C-terminal region of PP1 is replaced with the C-terminal 
region of PP2A, revealed that the recombinant PPase has 
increased sensitivity to okadaic acid. These findings are con-
sistent with the findings of Zhang et al. [32,33] and Huang et 
al. [35], providing further support for the importance of the 
ß 12/ß 13 loop and adjacent regions for the binding of okadaic 
acid and microcystin [32-35,46]. In contrast to the effects 
observed with okadaic acid, CRHM2 was inhibited by fostrie-
cin at concentrations similar to those needed to inhibit the 
activity of PP1. Thus, the high affinity fostriecin binding site 
of PP2A does not appear to be located in the same region as 
the okadaic acid and microcystin binding domain. The eluci-
234 A.H. Walsh et al.lFEBS Letters 416 (1997) 230-234 
dation of the crystal structures of PP2A and fostriecin should 
certainly aid in further defining the fostriecin binding domain. 
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